The bacterial lysate OM-85 Reduces Exacerbations and Oral Corticosteroid Use in Frequently Exacerbating Patients with T2-High Asthma: The OMREXA Real-World Evidence Study | Synapse
The bacterial lysate OM-85 Reduces Exacerbations and Oral Corticosteroid Use in Frequently Exacerbating Patients with T2-High Asthma: The OMREXA Real-World Evidence Study
The analysis aims to evaluate the effectiveness of OM-85 in reducing asthma exacerbations in patients with T2-high asthma.
Post hoc analysis of real-world evidence data
Focus on frequently exacerbating patients with T2-high asthma
Comparison of exacerbation rates before and after OM-85 administration
Significant reduction in asthma exacerbations noted
Decreased reliance on oral corticosteroids observed
Support for OM-85 as a therapeutic option for T2-high asthma
Abstract
This secondary post hoc analysis supports the therapeutic benefit of OM-85 in patients with T2-high asthma who have frequent exacerbations despite adherence to SoC asthma therapy.